Nektar Therapeutics

NKTR

$68.66

Name : Nektar Therapeutics

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $1,969,715,712.00

EPSttm : -9.73

Nektar Therapeutics

$68.66

3.25%

$2.31

NKTR — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

13.32

Margin Of Safety %

Put/Call OI Ratio

0.3

EPS Next Q Diff

-0.95

EPS Last/This Y

-2.43

EPS This/Next Y

-0.61

Price

68.6

Target Price

128.12

Analyst Recom

1.2

Performance Q

56.26

Upside

-293.5%

Beta

-0.77

Ticker: NKTR

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-02	NKTR	68.24	0.82	0.49	29144
2026-03-03	NKTR	68.16	0.83	0.36	30775
2026-03-04	NKTR	71.01	0.81	0.15	31909
2026-03-05	NKTR	72.4	0.78	0.18	32825
2026-03-06	NKTR	70.63	0.78	1.12	32918
2026-03-09	NKTR	69.28	0.79	0.46	32938
2026-03-10	NKTR	72.04	0.79	0.46	33335
2026-03-11	NKTR	73.33	0.77	2.16	33726
2026-03-12	NKTR	70.46	0.78	0.38	33389
2026-03-13	NKTR	70.36	0.78	0.40	33389
2026-03-17	NKTR	75.05	0.79	0.07	36076
2026-03-18	NKTR	73.26	0.70	0.05	38320
2026-03-19	NKTR	74.88	0.69	0.02	39484
2026-03-20	NKTR	72.41	0.63	0.47	41504
2026-03-23	NKTR	74.28	0.31	0.05	24355
2026-03-24	NKTR	72.96	0.31	0.22	24702
2026-03-25	NKTR	71.98	0.30	0.30	25385
2026-03-26	NKTR	70.98	0.30	0.43	25885
2026-03-27	NKTR	68.66	0.30	0.13	26524
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	NKTR	68.28	-55.3	-	-8.32
2026-03-03	NKTR	68.13	-55.3	-	-8.32
2026-03-04	NKTR	71.02	-55.3	-	-8.32
2026-03-05	NKTR	72.42	-55.3	-	-8.32
2026-03-06	NKTR	70.64	-55.3	-	-8.32
2026-03-09	NKTR	69.22	-55.3	-	-8.32
2026-03-10	NKTR	72.06	-55.3	-	-8.32
2026-03-11	NKTR	73.31	-55.3	-	-8.32
2026-03-12	NKTR	70.46	-55.3	-	-8.32
2026-03-13	NKTR	73.27	-55.3	-	-8.32
2026-03-17	NKTR	75.05	47.6	-	-11.72
2026-03-18	NKTR	73.26	47.6	-	-11.72
2026-03-19	NKTR	74.83	47.6	-	-11.72
2026-03-20	NKTR	72.19	47.6	-	-12.16
2026-03-23	NKTR	74.23	47.6	-	-12.16
2026-03-24	NKTR	72.92	47.6	-	-12.16
2026-03-25	NKTR	71.98	47.6	-	-12.16
2026-03-26	NKTR	70.89	47.6	-	-12.16
2026-03-27	NKTR	68.60	47.6	-	-12.16
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-02	NKTR	-2.70	11.02	17.86
2026-03-03	NKTR	-2.70	11.02	12.99
2026-03-04	NKTR	-2.70	11.02	12.99
2026-03-05	NKTR	-2.53	11.02	12.99
2026-03-06	NKTR	-2.53	11.02	12.99
2026-03-09	NKTR	-1.35	11.08	12.99
2026-03-10	NKTR	-1.35	11.08	12.99
2026-03-11	NKTR	-1.35	11.08	12.44
2026-03-12	NKTR	-0.76	11.08	12.44
2026-03-13	NKTR	-0.76	11.08	12.44
2026-03-17	NKTR	-0.76	25.83	12.44
2026-03-18	NKTR	-0.74	25.83	12.13
2026-03-19	NKTR	-0.74	25.83	12.13
2026-03-20	NKTR	-0.74	25.83	12.13
2026-03-23	NKTR	-0.74	24.27	12.13
2026-03-24	NKTR	-0.74	24.27	12.13
2026-03-25	NKTR	-0.74	24.27	13.32
2026-03-26	NKTR	-0.74	24.27	13.32
2026-03-27	NKTR	-0.74	24.27	13.32
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-1.29

Avg. EPS Est. Current Quarter

-1.89

Avg. EPS Est. Next Quarter

-2.24

Insider Transactions

-0.74

Institutional Transactions

24.27

Beta

-0.77

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

78.1

Max Drawdown 5-Year %

-97.9

Target Price

128.12

P/E

Forward P/E

PEG

P/S

35.66

P/B

15.58

P/Free Cash Flow

EPS

-10.22

Average EPS Est. Cur. Y

-12.16

EPS Next Y. (Est.)

-12.77

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-297.07

Relative Volume

0.67

Return on Equity vs Sector %

-210

Return on Equity vs Industry %

-193.7

EPS 1 7Days Diff

-0.4

EPS 1 30Days Diff

-0.3

EBIT Estimation

◆ NKTR Healthcare

$68.66

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

2/20

Pullback

9/25

Volume

9/15

Valuation

8/20

TP/AR

4/10

Options

8/10

RSI

49.6

Range 1M

40.6%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

6/25

Growth

7/30

Estimates

2/20

Inst/Vol

9/15

Options

8/10

EPS Yr

-3%

EPS NY

-22%

52W%

87.1%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +86.6% upside

Quality

6/30

Valuation

16/30

Growth

4/25

Stability

5/10

LT Trend

1/5

Upside

+86.6%

Quality

Nektar Therapeutics

Sector: Healthcare

Industry: Biotechnology

Employees: 63

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.

NKTR

Latest News

—

Caricamento notizie per NKTR…

stock quote shares NKTR – Nektar Therapeutics Stock Price stock today

news today NKTR – Nektar Therapeutics stock forecast ,stock prediction 2023 2024 2025

marketwatch NKTR – Nektar Therapeutics yahoo finance google finance

stock history NKTR – Nektar Therapeutics invest stock market

stock prices NKTR premarket after hours

ticker NKTR fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: NKTR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y